Clusterin mediates TRAIL resistance in prostate tumor cells.

  title={Clusterin mediates TRAIL resistance in prostate tumor cells.},
  author={David A. Sallman and Xianghong Chen and Bin Zhong and Danielle L. Gilvary and Junmin Zhou and Sheng Wei and Julie Y. Djeu},
  journal={Molecular cancer therapeutics},
  volume={6 11},
One of the major obstacles in curing prostate cancer is the development of drug resistance to docetaxel, which is the gold standard for the treatment of this disease. It is not only imperative to discover the molecular basis of resistance but also to find therapeutic agents that can disrupt the resistant pathways. Based on initial findings that docetaxel-resistant PC3-DR and DU145-DR prostate tumor cell lines express tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptors, we… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 29 extracted citations

Clusterin as a therapeutic target.

Expert opinion on therapeutic targets • 2017
View 2 Excerpts

Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology • 2015


Publications referenced by this paper.
Showing 1-10 of 34 references

The clinical trail of TRAIL.

European journal of cancer • 2006
View 3 Excerpts
Highly Influenced

Clusterin inhibits apoptosis by interacting with activated Bax

Nature Cell Biology • 2005
View 3 Excerpts
Highly Influenced

Apoptosis-based therapies and drug targets

Cell Death and Differentiation • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…